Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • News
    • News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
  • Toggle search form

[Disclosure] Hanwha Ocean (042660) Announces Subsidiary Hanwha Ocean USA Holdings Corp. Modified Scheduled Acquisition Date to ‘Undetermined’ for U.S. Sub-Affiliate Equity Investment

Posted on December 30, 2024July 18, 2026 By K-STOCK Editor No Comments on [Disclosure] Hanwha Ocean (042660) Announces Subsidiary Hanwha Ocean USA Holdings Corp. Modified Scheduled Acquisition Date to ‘Undetermined’ for U.S. Sub-Affiliate Equity Investment

Source Fact: Financial Supervisory Service DART / 2024-12-30

Disclosure Type: Decision on Acquisition of Shares and Investment Certificates of Other Corporations (Major Management Matters of Subsidiaries)

💡 3-Second Summary

Hanwha Ocean’s U.S. subsidiary, Hanwha Ocean USA Holdings Corp., has amended its disclosure regarding the equity investment in its affiliate, Hanwha Ocean USA International LLC, shifting the scheduled acquisition date from December 31, 2024, to ‘Undetermined’ and planning a re-disclosure upon finalization.

📊 1. [Summary of Key Disclosure Content and Major Figures]

  • Target Document for Amendment: Decision on Acquisition of Shares and Investment Certificates of Other Corporations (Major Management Matters of Subsidiaries) submitted on April 19, 2024
  • Reason for Amendment: Change in the scheduled date of acquisition
  • Reporting Entity (Subsidiary): Hanwha Ocean USA Holdings Corp. (An unlisted foreign subsidiary 100% owned by Hanwha Ocean)
  • Issuing Company (Recipient of Investment): Hanwha Ocean USA International LLC (Nationality: United States / Affiliate / Core Business: Maritime Service / Scheduled to become a subsidiary of Hanwha Ocean upon completion of this investment)
  • Amendments (Changes in Timeline Parameters):
    • Scheduled Date of Acquisition: (Before) 2024-12-31 → (After) – (Modified to Undetermined)
  • Details of Equity Acquisition (Initial parameters maintained):
    • Number of Shares to Acquire / Post-Acquisition Shares & Stake Ratio: Stated as item not applicable (-)
    • Acquisition Amount: KRW 185,746,500,000 (Approx. KRW 185.7B, converted based on the total of USD 135,000,000 using the trading reference rate of 1 USD = 1,375.90 KRW as of the board resolution date on April 19, 2024)
  • Proportion to Financial Metrics: Proportion to recent revenue or assets is omitted / Consolidated total assets of the controlling company (Hanwha Ocean) stand at KRW 13,944,800,000,000 (Based on the consolidated financial statements at the end of 2023, rounded to the nearest KRW 100 million)
  • Method & Purpose of Acquisition: Participation in a stockholder-allocated paid-in capital increase (Cash acquisition) / Participation in a capital increase to secure investment resources
  • Initial Board Resolution Date (Decision Date): April 19, 2024 (Based on the board approval date of the subsidiary, Hanwha Ocean USA Holdings Corp.)
  • Affiliate Information: Both entities were incorporated in 2023; summary financial status and underlying subsidiary asset entries are omitted

📈 2. [Expert View: What This Disclosure Means for Investors]

This disclosure represents an official statutory amendment notifying that the planned execution timeline of the equity investment transaction handled by the subsidiary, Hanwha Ocean USA Holdings Corp., for its affiliate, Hanwha Ocean USA International LLC, has been modified. According to the updated parameters outlined, the final target acquisition date, originally scheduled for December 31, 2024, has been shifted to an ‘Undetermined’ status.

According to the confirmed planned facts appended to the critical note segment, following this shift to an undetermined acquisition date, the subsidiary plans to execute the equity investment over the period depending on the actual progress of the local business, and an updated disclosure is scheduled to be filed once the final timeline is confirmed. The target financing scale is maintained at its initial parameters of approximately KRW 185.7B (USD 135.0M), and the structural transition framework under which Hanwha Ocean USA International LLC will be incorporated into the consolidated subsidiary structure remains unchanged. The text notes that the KRW-converted value remains subject to change depending on historical foreign exchange fluctuations at the time of actual capital deployment. The document does not state how this timeline postponement will impact potential operational timelines of the local entity, Hanwha Ocean’s detailed subsequent consolidated financial statements, or future stock price trends. Therefore, instead of assuming prospective operational impacts using external assumptions, investors should interpret this disclosure focusing strictly on the conditional timeline adjustments and the planned re-filing obligation upon finalization.

📝 Editor’s Comment (by K-STOCK Editor)

Hanwha Ocean’s recent amendment establishes a structural re-scheduling for the equity allocation pipeline of its U.S. subsidiary, entailing a cash investment value maintained at approximately KRW 185.7B. The core fact remains that the final acquisition target date has been removed from immediate schedules to an undetermined timeline, converting the investment execution into a layout that tracks local business progress over the period.

The primary variables and checkpoints that investors need to monitor moving forward are confined to subsequent amended filings regarding the finalized transaction timeline and foreign exchange rate fluctuations during the actual capital injections. As outlined in the text, the acquisition date remains undetermined and the investment will be executed over the period depending on business progress, meaning the specified schedule and metrics carry a potential likelihood of changing during the actual execution process. Since prospective asset allocations or explicit quantitative profit targets are not specified in the original text, over-optimism derived from external assumptions should be avoided, and investors should rely strictly on verified parameters to be submitted in subsequent formal updates as their primary checkpoints.

📢 Disclaimer & Source Information

Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service electronic disclosure system (DART).

Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For inquiries regarding compliance or copyright requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Shipbuilding

Post navigation

Previous Post: [Disclosure] Hanwha Ocean (042660) Files Amendment for Acquisition of Shares in U.S. Subsidiary Hanwha Ocean USA Holdings Corp.: Scheduled Acquisition Date Modified to ‘Undetermined’
Next Post: [Disclosure] Hanwha Ocean 042660, Final Acquisition Date for KRW 363.3B Subsidiary Rights Offering Changed to ‘Undetermined’

Related Posts

[Disclosure] Hanwha Aerospace (012450) Amends Paid-in Capital Increase Outlining First Round Price at KRW 684,000 and Revised Capital Uses Disclosures
[Disclosure] PSK Holdings (031980) Extends Completion Date for KRW 41.3B R&D Campus Construction to April 2024 Semiconductors
[Disclosure] Hanwha Ocean (042660) Files Amendment for Single Sales/Supply Contract to Extend Contract End Date to Late December 2025 for 1 WTIV Order Disclosures
[Disclosure] Hanwha Ocean (042660) Files Amendment to Adjust Contract End Date to Undefined (-) for KRW 1.162T Submarine Project with Indonesian Ministry of Defense, Reporting Non-activation Status Disclosures
[Disclosure] Samsung Biologics (207940) Extends Non-Disclosure Deadline to 2031 for KRW 588.8B CMO Contract Disclosures
[Disclosure] Celltrion (068270) Obtains European EMA Approval for Phase 3 Clinical Trial Plan Part 1 of ‘CT-P13 SC (Remsima SC)’ in Pediatric Ulcerative Colitis Patients Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Alteogen (196170) Establishes August 6 as Record Date for Bonus Issue Share AllotmentJuly 16, 2026
  • [Disclosure] Alteogen (196170) Announces Trading Suspension and Resumption Schedule for Stock Futures and OptionsJuly 16, 2026
  • [Disclosure] Alteogen (196170) Temporarily Suspends Plans for Relisting on the KOSPI MarketJuly 16, 2026
  • [Disclosure] Alteogen (196170) Announces Temporary Trading Suspension on July 16 Due to Bonus Issue DecisionJuly 16, 2026
  • [Disclosure] Alteogen (196170) Decides on Bonus Issue of 0.3 Shares per 1 Common and Preferred ShareJuly 16, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme